FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
10 letters match. Newest first.
-
DrugsSanrace Biotechnology Co., Ltd.
FDA warns Sanrace Biotechnology over CGMP failures in OTC drugs, including missing identity tests and no process validation.
High risk -
DrugsEurofins SF Analytical Laboratories, Inc.
FDA warned Eurofins SF Analytical Laboratories, a contract drug-testing lab, that it kept incomplete microbial test records and skipped required investigations.
High risk -
DrugsSuretec Innovations, LLC
Suretec Innovations failed manufacturing quality rules for OTC sanitizing wipes and did not list a private-label wipe.
High risk -
DrugsLico Industries, LLC., d.b.a. American Towelette Company
FDA warns Lico Industries (American Towelette) that its OTC drug wipes are adulterated due to poor quality oversight, dirty equipment and falsified records.
High risk -
DrugsSato Pharmaceutical Co., Ltd.
FDA says Sato Pharmaceutical's sterile OTC drug line had contamination and stability failures.
High risk -
DrugsRespilon Production S.R.O.
FDA found Respilon, a Czech OTC drug maker, lacked ingredient identity testing, stability data and process validation.
Medium -
DrugsMicrobiological Testing & Consulting, LLC
FDA warned contract testing lab Microbiological Testing & Consulting over CGMP violations in drug product microbiological testing.
High risk -
DevicesDiasol, Inc.
Diasol sold unapproved citric acid hemodialysis disinfectants and had quality system violations, FDA says.
High risk -
DrugsSignature Formulations, LLC
FDA says Signature Formulations made OTC drugs on shared equipment without adequate controls, risking hormone contamination.
High risk -
DrugsIntegrity Partners Group
FDA warns Integrity Partners Group about manufacturing failures at its Chemisphere drug plant, including inadequate testing, supplier verification, cleaning, and process validation.
High risk